Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M43.3Revenue $M32.2Net Margin (%)0Z-Score3.7
Enterprise Value $M13.6EPS $-0.8Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book1.610-y EBITDA Growth Rate %0Quick Ratio11.4Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio11.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-37.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-48.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M34.1ROI % (ttm)-107.2Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

BLRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about BLRX :

    Quarterly/Annual Reports about BLRX:

      News about BLRX:

      Articles On GuruFocus.com

      More From Other Websites
      BioLineRx Reports Third Quarter 2014 Financial Results Nov 10 2014
      BioLineRx Reports Third Quarter 2014 Financial Results Nov 10 2014
      BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment Nov 05 2014
      BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment Nov 05 2014
      BioLineRx to Report Third Quarter 2014 Results on November 10, 2014 Nov 03 2014
      BioLineRx to Report Third Quarter 2014 Results on November 10, 2014 Nov 03 2014
      BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy... Nov 03 2014
      BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy... Nov 03 2014
      BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for... Oct 31 2014
      BioLineRx Reports Publication in Peer Review Journal of Results from Previous Phase 1/2 Trial for... Oct 31 2014
      BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations Sep 17 2014
      [$$] Three Biotechs Ready to Partner Up Sep 05 2014
      BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization... Sep 03 2014
      BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York Sep 02 2014
      BioLineRx Receives Notice of Allowance for US Patent on BL-7010 Covering Use of Novel Polymer in... Aug 21 2014
      BioLineRx Reports Second Quarter 2014 Financial Results Aug 06 2014
      BioLineRx to Report Second Quarter 2014 Results on August 6, 2014 Jul 30 2014
      BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment Jul 16 2014
      BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment Jul 16 2014
      BioLineRx to Commence BL-8040 Study Jun 19 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK